Wall Street analysts forecast that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will report earnings of $0.02 per share for the current quarter, Zacks reports. Three analysts have made estimates for Amphastar Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at $0.08. Amphastar Pharmaceuticals posted earnings per share of $0.14 in the same quarter last year, which would indicate a negative year over year growth rate of 85.7%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 14th.

According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full-year earnings of $0.26 per share for the current financial year, with EPS estimates ranging from $0.11 to $0.39. For the next financial year, analysts forecast that the company will report earnings of $0.66 per share, with EPS estimates ranging from $0.37 to $0.92. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. The company had revenue of $65.20 million for the quarter, compared to the consensus estimate of $63.40 million. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The firm’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.23 earnings per share.

Several brokerages have recently issued reports on AMPH. Piper Jaffray Companies set a $20.00 target price on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, July 29th. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Jefferies Group LLC restated a “buy” rating and set a $19.00 price target (down previously from $20.00) on shares of Amphastar Pharmaceuticals in a research report on Friday, August 11th. BMO Capital Markets reiterated a “hold” rating and issued a $16.00 price objective on shares of Amphastar Pharmaceuticals in a report on Monday, July 31st. Finally, ValuEngine lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $20.14.

Shares of Amphastar Pharmaceuticals (AMPH) traded down 0.75% during trading on Tuesday, reaching $18.55. The company had a trading volume of 259,616 shares. Amphastar Pharmaceuticals has a 52 week low of $12.05 and a 52 week high of $21.75. The stock’s 50-day moving average price is $15.92 and its 200-day moving average price is $16.01. The company has a market capitalization of $856.92 million, a PE ratio of 240.91 and a beta of 1.69.

Amphastar Pharmaceuticals announced that its board has authorized a stock repurchase plan on Wednesday, August 9th that permits the company to repurchase $20.00 million in shares. This repurchase authorization permits the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/03/amphastar-pharmaceuticals-inc-amph-expected-to-announce-earnings-of-0-02-per-share.html.

In other news, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $14.80, for a total transaction of $74,000.00. Following the completion of the transaction, the director now directly owns 33,844 shares in the company, valued at $500,891.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $14.81, for a total value of $148,100.00. Following the transaction, the director now owns 33,844 shares of the company’s stock, valued at $501,229.64. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rothschild Asset Management Inc. purchased a new position in Amphastar Pharmaceuticals during the 1st quarter valued at about $9,056,000. Citadel Advisors LLC grew its holdings in shares of Amphastar Pharmaceuticals by 1,823.3% in the first quarter. Citadel Advisors LLC now owns 355,566 shares of the company’s stock valued at $5,156,000 after purchasing an additional 337,079 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Amphastar Pharmaceuticals by 25.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,331,842 shares of the company’s stock worth $23,786,000 after buying an additional 270,654 shares during the period. Vanguard Group Inc. increased its stake in Amphastar Pharmaceuticals by 10.8% during the 2nd quarter. Vanguard Group Inc. now owns 2,414,797 shares of the company’s stock worth $43,128,000 after buying an additional 235,033 shares during the period. Finally, UBS Asset Management Americas Inc. increased its stake in Amphastar Pharmaceuticals by 143.0% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 362,947 shares of the company’s stock worth $6,482,000 after buying an additional 213,572 shares during the period. 44.26% of the stock is currently owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.